A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia by Pratz, Keith W, Kaplan, Jason, Levy, Moshe, Bixby, Dale, Burke, Patrick W, Erba, Harry, Wise-Draper, Trisha M, Roboz, Gail J, Papadantonakis, Nikolaos, Rajkhowa, Trivikram, Hernandez, Daniela, Dobler, Iwona, Gregory, Richard C, Li, Cheryl, Wang, Shining, Stumpo, Kate, Kannan, Karuppiah, Miao, Harry, Levis, Mark

Get full text

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma by Gordon, Leo I, Kaplan, Jason B, Popat, Rakesh, Burris, 3rd, Howard A, Ferrari, Silvia, Madan, Sumit, Patel, Manish R, Gritti, Giuseppe, El-Sharkawi, Dima, Chau, Ian, Radford, John A, Pérez de Oteyza, Jaime, Zinzani, Pier Luigi, Iyer, Swaminathan, Townsend, William, Karmali, Reem, Miao, Harry, Proscurshim, Igor, Wang, Shining, Wu, Yujun, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc

Get full text

Abstract A067: Evaluation of large-scale quantitative systems pharmacology model predictions of in vitro cancer cell line sensitivity to TAK-659, an investigational oral spleen tyr... by Abbasi, Taher, Vali, Shireen, Williams, Miguel, Sappal, Jessica, Li, Cong, Shin, Hyunjin, Gregory, Rick, Wu, Yujun, Wang, Shining, Stumpo, Kate, Bottino, Dean

Get full text

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma by Phillips, Tycel J., Salles, Gilles, Landsburg, Daniel J., Gritti, Giuseppe, Patel, Krish, Tilly, Herve, Thieblemont, Catherine, Townsend, William, Ferrari, Silvia, Stumpo, Kate F., Katyayan, Shilpi, Li, Cheryl, Miao, Harry, Proscurshim, Igor, Gopal, Ajay K.

Get full text

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659... by Gordon, Leo I, Karmali, Reem, Kaplan, Jason B, Popat, Rakesh, Burris, 3rd, Howard A, Ferrari, Silvia, Madan, Sumit, Patel, Manish R, Gritti, Giuseppe, El-Sharkawi, Dima, Chau, F Ian, Radford, John, de Oteyza, Jaime Pérez, Zinzani, Pier Luigi, Iyer, Swaminathan P, Townsend, William, Miao, Harry, Proscurshim, Igor, Wang, Shining, Katyayan, Shilpi, Yuan, Ying, Zhu, Jiaxi, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc

Get full text

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) by Pratz, Keith, Levis, Mark J., Morris, John C, Wise-Draper, Trisha, Levy, Moshe, Bixby, Dale L., Burke, Patrick, Hernandez, Daniela, Stumpo, Kate, Kannan, Karuppiah, Sheldon-Waniga, Emily, Wang, Shining, Zhang, Steven, Shou, Yaping, Altman, Jessica K., Kaplan, Jason, Frankfurt, Olga

Get full text

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts by Kaplan, Jason, Gordon, Leo I., Rambaldi, Alessandro, Gritti, Giuseppe, Popat, Rakesh, Burris, Howard A., Patel, Manish R, Madan, Sumit, Chau, Ian, Radford, John A., Iyer, Swami P., Perez De Oteyza, Jaime, Zinzani, Pier Luigi, Wang, Shining, Sheldon-Waniga, Emily, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc

Get full text

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies by Petrich, Adam M., Gordon, Leo I., Infante, Jeffrey R., Madan, Sumit, Giles, Francis J., Nimeiri, Halla S., Kaplan, Jason B., Stumpo, Kate, Zhang, Bin, Faucette, Stephanie, Shou, Yaping, Shih, Kent C.

Get full text

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies by Kaplan, Jason B, Gordon, Leo I, Infante, Jeffrey R, Popat, Rakesh, Rambaldi, Alessandro, Madan, Sumit, Patel, Manish R., Gritti, Giuseppe, Ng, Chin-Hin, Chau, Ian, Radford, John A, de Oteyza, Jaime Perez, Zinzani, Pier Luigi, Faucette, Stephanie, Sheldon-Waniga, Emily, Williams, Miguel, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc

Get full text

Abstract CT243: Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TN... by Cooper, Benjamin, Chmura, Steven J., Luke, Jason J., Shiao, Stephen L., Basho, Reva K., Iams, Wade T., Page, David B., Li, Cong, Gregory, Richard C., Shaw, Michael H., Horn, Kristin H., Gibbs, John P., Appleman, Vicky A., Berger, Allison J., Abu-Yousif, Adnan O., Lineberry, Neil B., Stumpo, Kate F., Elfiky, Aymen, Gerber, Naamit K.

Get full text